

Request for Prior Authorization GRANULOCYTE COLONY STIMULATING

FAX Completed Form To | (877) 733-3195

FACTOR

Provider Help Desk | (844) 236-1464

(PLEASE PRINT – ACCURACY IS IMPORTANT)

| IA Medicaid Member ID # Patient name I | DOB |
|---|---------------------|
| Patient address | |
| | |
| Provider NPI Prescriber name F | hone |
| Prescriber address F | ax |
| Pharmacy name Address H | Phone |
| Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned. | |
| Pharmacy NPI Pharmacy fax NDC | |
| | |
| Prior authorization is required for therapy with granulocyte colony stimulating factor agents. Payment for non-preferred granulocyte colony stimulating factor agents will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent(s). Laboratory values for complete blood and platelet count must be obtained as directed by the manufacturer's instructions. Dosage reduction and discontinuation of therapy may be required based on the manufacturer's guidelines. | |
| Preferred Non-Preferred | |
| Fylnetra Neupogen Fulphila Leukine Rolvedon Stimufend Ziextenzo Granix Nyvepria Neulasta Nivestym Udencya Zarxio Releuko Releuko Releuko Rolvedon Rolvedon Rolvedon | |
| Strength Dosage Instructions Q | uantity Days Supply |
| Diagnosis (or indication for the product): Prevention or treatment of febrile neutropenia in patients with malignancies who are receiving myelosuppressive anticancer therapy. Treatment of neutropenia in patients with malignancies undergoing myeloablative chemotherapy followed by a bone marrow transplant. Mobilization of progenitor cells into the peripheral blood stream for leukapheresis collections to be used after myeloablative chemotherapy. Treatment of congenital, cyclic, or idiopathic neutropenia in symptomatic patients. On current chemotherapy drug(s) that would cause severe neutropenia (specify) Other condition specify) | |
| Absolute Neutrophil Count (ANC): | |
| Dates of routine CBC: | |
| Platelet Counts: | |
| | |
| Pertinent Lab data: | |
| Pertinent Lab data: Previous therapy (include drug name, strength and exact date ranges): | |
| | |
| Previous therapy (include drug name, strength and exact date ranges): | |
| Previous therapy (include drug name, strength and exact date ranges): Reason for use of Non-Preferred drug requiring prior approval: | |

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.